Only the identification of neurohumoral activation as a central detrimental feature of HF and subsequent development of neurohumoral antagonists (angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, β-adrenergic receptor antagonists, aldosterone receptor antagonists) has led to great advances in the treatment of HF. Here, NR3C2 is linked to hydrops fetalis.